Literature DB >> 8203951

Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

P E Spronk1, E J ter Borg, M G Huitema, P C Limburg, C G Kallenberg.   

Abstract

OBJECTIVES: To assess serial activation of T-cell subsets in relation to auto-antibody production and the occurrence of disease exacerbations in patients with systemic lupus erythematosus (SLE).
METHODS: To study the possible role of T-cells in the pathophysiology of the disease, 16 consecutive exacerbations were prospectively studied in a cohort of patients with SLE, and serial plasma levels of sIL-2R, sCD4, and sCD8 preceding and during these exacerbations were determined. Levels of these molecules were related to total IgM and IgG, and anti-dsDNA.
RESULTS: During major disease exacerbations (n = 6), levels of sIL-2R increased significantly (p < 0.001). Levels of sCD4 were predominantly in the normal range, whereas levels of sCD8 were frequently increased. No change in levels of both molecules could be detected in the period before the exacerbation. During minor exacerbations (n = 10), levels of sIL-2R remained stable. Levels of sCD4, however, tended to drop, whereas levels of sCD8 tended to rise. No correlations were found between sIL-2R, sCD4 or sCD8 on the one hand, and total IgM, IgG, or anti-dsDNA on the other.
CONCLUSIONS: Levels of sIL-2R are increased, and rise before major exacerbations of SLE. Levels of sCD4 and sCD8, however, are not related to levels of sIL-2R, and do not reflect B-cell activation, nor disease activity during exacerbations of SLE. Thus for the clinical follow up of SLE measurement of levels of sCD4 or sCD8 is of limited value.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203951      PMCID: PMC1005301          DOI: 10.1136/ard.53.4.235

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  The first international standard for antibodies to double stranded DNA.

Authors:  T E Feltkamp; T B Kirkwood; R N Maini; L A Aarden
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

3.  Soluble CD8 in patients with rheumatic diseases.

Authors:  J A Symons; N C Wood; F S di Giovine; G W Duff
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

4.  Elevated soluble CD8 in the synovial fluid from patients with rheumatoid arthritis.

Authors:  A B Carpenter; C H Eisenbeis; S Carrabis; M C Brown; S H Ip
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

Authors:  E J ter Borg; G Horst; E J Hummel; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1990-05

7.  Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE).

Authors:  H Groen; M Aslander; H Bootsma; T W van der Mark; C G Kallenberg; D S Postma
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release.

Authors:  D Donati; D Degiannis; L Homer; L Gastaldi; J Raskova; K Raska
Journal:  Nephron       Date:  1991       Impact factor: 2.847

9.  Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.

Authors:  N L Carteron; C L Schimenti; D Wofsy
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

10.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

View more
  3 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?

Authors:  Human Adams; Rob van Rooij; Coline H M van Moorsel; Marcela Spee-Dropkova; Jan C Grutters; Ruth G Keijsers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 3.  Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review.

Authors:  Noémie Gensous; Aurélie Marti; Thomas Barnetche; Patrick Blanco; Estibaliz Lazaro; Julien Seneschal; Marie-Elise Truchetet; Pierre Duffau; Christophe Richez
Journal:  Arthritis Res Ther       Date:  2017-10-24       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.